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Accepted 6 January 2018As a continuation of our search for biologically active mushroom species the present study investigates in vitro
antidiabetic properties of six edible and medicinal mushroom species: Agaricus blazeiMurrill, Coprinus comatus
(O.F.Müll.) Pers., Cordyceps militaris (L.) Fr., Inonotus obliquus (Ach. ex Pers.) Pilát, Morchella conica Pers. and
Phellinus linteus Berk. & M.A. Curtis. In vitro assays on α-amylase and α-glucosidase enzyme inhibition were
performed with methanolic extracts of the selected mushrooms. Furthermore, we calculated the necessary
daily intake of mushroom extracts and dry mushroom powders based on the equivalent doses of therapeutic
drug acarbose given to diabetic patients per day. Our comparative study on enzyme inhibition showed that the
most promising potential is ascribed to I. obliquus extract, while no inhibition of α-amylase was recorded with
M. conica and C. militaris methanolic extract at the tested concentration. This comparative study is the ﬁrst
highlighting in vitro antidiabetic potential by inhibition of α-amylase and α-glucosidase with methanolic ex-
tracts; which makes the investigated species more promising for the diabetes type-2 treatment by an additional
and different mechanism of action.
© 2018 Published by Elsevier B.V. on behalf of SAAB.Keywords:
Diabetes mellitus
α-Amylase
α-Glucosidase
Mushroom
Edible and medicinal1. Introduction
Mushrooms are important dietary components in some cultures,
consumed in daily diet as supplementary food since olden times
(Soković et al., 2016). Mushroom extracts are increasingly consumed
because of their health beneﬁcial effects, including the enhancement
of immune function and antitumor activity (Popović et al., 2013). It is
conﬁrmed that mushroom extracts contain diverse compounds such
as alkaloids, ﬁbers, lectins, protein, polyphenols and polysaccharides,
which are contributing to their biological activities (Popović et al.,
2013). Mushrooms are thought to exert many pharmacological func-
tions such as antitumor, immunomodulatory, antigenotoxic, antioxi-
dant, anti-inﬂammatory, hypocholesterolemic, antihypertensive,
antiplatelet-aggregating, antihyperglycemic, antimicrobial and other
activities (Lindequist, 2013; Paterson and Lima, 2014). Mushrooms as
functional food and dietary supplements can help in the intervention
of sub-health states and may prevent the full-blown consequences of
life-threatening diseases. An equilibrated diet linked with the mush-
room consumption has an advantage of the nutritional/medicinal fea-
tures of mushrooms (Soković et al., 2016) and their pharmacologicalf SAAB.applications. The term “mushroom” is used here for a medicinal/edible
fruiting body of higher fungi.
Diabetes mellitus is a chronic disorder of metabolism followed by ab-
normal rise in plasma glucose levels, as a consequence of unequilibrated
insulin production and/or insensitivity to the effect of this hormone in
signal transduction of cellular receptors. These metabolic changes are
accompanied by modiﬁcations in carbohydrate, lipid and protein me-
tabolism. Most of the diabetes type 2 complications in patients are due
to hyperglycemia as their main cause (Oritz et al., 2007; Shobana
et al., 2009). One of the effective strategies for diabetes type-2 manage-
ment is the inhibition of complex polysaccharide hydrolysis by pancre-
atic α-amylase and absorption limitation of glucose by inhibiting
intestinal α-glucosidase enzyme. Acarbose, miglitol, voglibose are
commercial drugs used for α-glucosidase inhibition in the control
of the diabetic disease (Saito et al., 1998). Chronic α-amylase and
α-glucosidase inhibitions may be useful in the management of type-2
diabetes and obesity (Melo et al., 1999; Koike, 2005). The drugs cur-
rently used as reversible inhibitors of α-amylase and α-glucosidase
for the treatment of diabetic patients exhibit side effects such as abdom-
inal distension, meteorism, bloating, ﬂatulence and possibly diarrhea
(Fujisawa et al., 2005).
To continue our investigations (Stojković et al., 2013; Reis et al.,
2014; Stojković et al., 2014; Bizarro et al., 2015; Glamočlija et al.,
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we designed this study to explore the antidiabetic properties of six
edible and medicinal mushrooms: Agaricus blazei Murrill, Coprinus
comatus (O.F.Müll.) Pers., Cordyceps militaris (L.) Fr., Inonotus obliquus
(Ach. ex Pers.) Pilát,Morchella conica Pers. and Phellinus linteus Berk. &
M.A. Curtis. In vitro assays on α-amylase and α-glucosidase enzyme
inhibition were performed with methanolic extracts of the selected
mushrooms.
2. Material and methods
2.1. Mushroom samples
Six edible andmedicinal mushroom species were used in this study:
A. blazei Murrill (commercial sample), C. comatus (O.F.Müll.) Pers.
(collected - wild growing in Serbia), C. militaris (L.) Fr. (commercial sam-
ple), I. obliquus (Ach. ex Pers.) Pilát (commercial sample),M. conica Pers.
(collected - wild growing in Serbia) and P. linteus Berk. & M.A. Curtis
(commercial sample). The origin of samples, identiﬁcation and prepara-
tion of dried powder were described previously (Stojković et al., 2013;
Reis et al., 2014; Stojković et al., 2014; Bizarro et al., 2015; Glamočlija
et al., 2015; Vieira et al., 2016).
2.2. Extraction procedures
Mushroom samples (~5 g)were extracted by stirringwith 150mLof
methanol (−20 °C at 150 rpm) for 24 h and subsequently ﬁltered
through Whatman No. 4 paper. The residue was then extracted with
an additional portion of methanol. The combined methanolic extracts
were evaporated under reduced pressure (rotary evaporator Büchi
R-210; Flawil, Switzerland) to dryness.
2.3. α-Amylase and α-glucosidase inhibition assays
Mushroomextracts at different concentrationsdissolved to 500 μL and
500 μL of 0.02 M sodium phosphate buffer (pH 6.9 with 0.006 M NaCl)
containing Porcine pancreatic α-amylase (Sigma Aldrich, Germany)
(0.5mg/mL)were incubated at 25 °C for 10min. Then, 500 μL of 1% starch
solution in 0.02 M sodium phosphate buffer (pH 6.9 with 0.006 M NaCl)
was added to each tube. The reaction mixtures were incubated at 25 °C
for 10 min and stopped with 1.0 mL of dinitrosalicylic acid color reagent.
Thereafter, the mixture was incubated in a boiling water bath for 5 min
and cooled to room temperature. The reaction mixture was then diluted
by adding 10 mL of distilled water, and absorbance measured at 540 nm
using the spectrophotometer (Agilent 8453, Agilent Technologies,
Waldbronn, Germany).
Mushroom extracts at different concentrations dissolved to 50 μL
and 100 μL of α-glucosidase (Sigma Aldrich, Germany) solution
(1.0 U/mL) in 0.1 M phosphate buffer (pH 6.9) was incubated at 25 °C
for 10 min. Then, 50 μL of 5 mM p-nitrophenyl-α-D-glucopyranoside
solution in 0.1 M phosphate buffer (pH 6.9) was added. The mixturesTable 1
Inhibitory potential of mushroom species on α-amylase and α-glucosidase linked to type-2 di
Mushroom species Yield of extracts (%) α-Amylase inhibition;
IC50 (μg/mL)
α-Glucosidase inhib
IC50 (μg/mL)
Agaricus blazei 14.24 1719.20 ± 89.53 357.23 ± 20.11
Coprinus comatus 10.57 714.45 ± 44.44 322.74 ± 11.21
Cordyceps militaris 13.25 nab 415.66 ± 36.12
Inonotus obliquus 12.23 830.32 ± 28.24 220.31 ± 7.37
Morchella conica 15.41 na 521.12 ± 16.45
Phellinus linteus 13.73 1479.46 ± 92.86 477.33 ± 17.55
Acarbose – 87.15 ± 2.93 39.23 ± 5.41
a Calculated on the basis of α-glucosidase inhibition.
b na— not active at the tested concentrations.were incubated at 25 °C for 5 min. Then, 2 mL of Na2CO3 was added to
terminate the reaction before reading the absorbance at 405 nm in the
spectrophotometer (Agilent 8453, Agilent Technologies, Waldbronn,
Germany).
Theα-amylase andα-glucosidase inhibitory activitieswere expressed
as percentage of inhibition (IC50). Acarbosewas used as a positive control
(Worthington, 1993; Apostolidis et al., 2007).
3. Results and discussion
The results ofα-amylase and α-glucosidase inhibition linked to dia-
betes type-2 therapy are summarized in Table 1. C. comatusmethanolic
extract had the most prominent inhibitory activity on α-amylase with
IC50 714.45 μg/mL, while C. militaris and M. conica did not have inhibi-
tory potential on this enzyme. All of the investigatedmushroom species
inhibited α-glucosidase with I. obliquus as the most potent inhibitor
among the studied species (IC50 220.31 μg/mL).
Table 1 also summarizes calculations of the daily intake of mush-
room methanolic extracts and dry mushroom powders necessary to
achieve the same effect as commercial therapeutic drug acarbose on
the daily basis. Acarbose is given to diabetic patients in an initial dose
of 3 × 25 mg per day. Calculations were done on the basis of α-
glucosidase inhibition by acarbose. The lowest daily intake of mushroom
powder was predicted for I. obliquus with the dose of 3 × 1.148 g/day,
while the highest was predicted for P. linteus 3 × 2.215 g/day (Table 1).
Kim et al. (2005) demonstrated that β-glucans and their enzymati-
cally hydrolyzed oligosaccharides from Agaricus brasiliensis (syn.
A. blazei) show the activities of antihypercholesterolemic,
antihypertriglyceridemic, antiarteriosclerotic and antihyperglycemic, in-
dicating antidiabetic activity in diabetic rats. The data suggested that
both β-glucans and oligosaccharides might enhance insulin secretion
from pancreatic islets as well as proliferation of islets in diabetic or nor-
mal rats (Kim et al., 2005). The results of our study showed that A. blazei
could also have an inhibitory inﬂuence on key enzymes involved in the
degradation of complex sugars (Table 1), thus delaying the process of
glucose uptake. Our previous study (Stojković et al., 2014) on chemical
composition of A. blazei revealed that this species possessed oxalic,
malic and fumaric organic acids. The total content of organic acids was
1.87 g per 100 g dw. The phenolic acids found in the studied mushroom
were p-coumaric acid (0.28 mg per 100 g dw) and cinnamic acid
(0.12 mg per 100 g dw), (Stojković et al., 2014). Different compounds
present in methanolic extracts and their different combinations are
probably linked to A. blazei enzyme inhibitory potential.
Recent studies described in vivo antidiabetic activity of different ex-
tracts and fractions of C. comatus (Yamaç et al., 2009; Ding et al., 2010;
Zhou et al., 2015). According to our knowledge, no previous records
were published on α-amylase and α-glucosidase enzyme inhibition
with C. comatus methanolic extract. Methanolic extract of C. comatus
studied here had inhibitory potential on both enzymes (Table 1). Re-
garding C. comatus, our previous study (Stojković et al., 2013) revealed
organic acid proﬁle, with ﬁve different compounds namely oxalic,abetes treatment.
ition; mg of extracts per day equivalent
to acarbose 3 × 25 mg tablets
given to a diabetic patient dailya
g of dry mushroom powder per day
equivalent to acarbose 3 × 25 mg tablets
given to a diabetic patient dailya
3 × 227.65 3 × 1.598
3 × 205.67 3 × 1.945
3 × 264.88 3 × 1.999
3 × 140.40 3 × 1.148
3 × 332.09 3 × 2.155
3 × 304.19 3 × 2.215
– –
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studied sample revealed the presence of dominant p-hydroxybenzoic
acid (0.09 mg/100 g) and presence of p-coumaric acid, as also the
related compound cinnamic acid (Stojković et al., 2013). Phenolic
compounds and organic acids are probably related to the anti-diabetic
activity investigated herein.
Water and polysaccharidic extracts of C. militaris previously showed
antidiabetic properties in diabetes induced rats (Liu et al., 2016). Our
study showed that methanolic extract of C. militaris did not inhibit the
activity of α-amylase (Table 1), while it had inhibitory potential on
α-glucosidase. A recent study showed that water extract of C. militaris
had inhibitory activities on α-glucosidase with values of 45.77% with
0.1 mg/mL, 54.76% with 0.25 mg/mL, 58.74% with 0.5 mg/mL, and
60.5%with 1.0mg/mL (Kim et al., 2017). The organic acidwe found pre-
viously in higher amounts in C. militaris was citric acid 7.97 g/100 g
(Bizarro et al., 2015). Regarding phenolic acids, p-hydroxybenzoic
acid was the only compound found in the studied species
(0.02 mg/100 g dw). However, cinnamic acid was also found
(0.11 mg/100 g dw), (Bizarro et al., 2015). The link between chemical
composition of methanolic extract of C. militaris and the enzyme inhib-
itory activity certainly exists.
Water extracts and polysaccharidic fractions of I. obliquus are re-
corded to possess in vivo antidiabetic properties (Qin et al., 2015). Ex-
tract of I. obliquus tested in our study possessed inhibitory potential of
both enzymes investigated (Table 1). A previous study by Ying et al.
(2014) revealed terpenoids from this species as inhibitors of glucosidase.
In our previous study (Glamočlija et al., 2015) oxalic acid was the only
organic acid detected in the extract of I. obliquus (72 mg/g extract). The
phenolic acids found were gallic, protocatechuic and p-hydroxybenzoic
acids, as also the related compound cinnamic acid (Glamočlija et al.,
2015). Relation between organic, phenolic acids, their combination in
the extract and antidiabetic activity explored herein certainly exists.
According to our knowledge, no previous studies were published on
M. conica antidiabetic activity. Our results indicate that methanolic
extract of this species did not inhibit α-amylase, while α-glucosidase
was inhibited (Table 1). RegardingM. conica organic acid proﬁle, previ-
ously (Vieira et al., 2016) we have quantiﬁed three different organic
acids: oxalic, quinic, and fumaric acids. The phenolic compounds gallic
and p-hydroxybenzoic acids were only present in the wild growing
sample, as well as cinnamic acid.
A polysaccharide isolated from P. linteus has previously shownhypo-
glycemic properties in alloxan-induced diabeticmice (Zhao et al., 2014).
P. linteus methanolic extract exhibited enzyme inhibitory potential in
this study (Table 1). The hydrophilic compounds recorded in P. linteus
earlier (Reis et al., 2014) were only organic acids — oxalic acid was the
only detected molecule (0.295 g/100 g dw).
The investigated mushroom species possessed antidiabetic proper-
ties regarding the inhibition of the enzymes investigated. C. militaris
andM. conica failed to inhibit the activity ofα-amylase, while inhibiting
the activity of α-glucosidase. I. obliquus methanolic extract was the
most potent inhibitor ofα-glucosidase, while C. comatus has the highest
potential in inhibition of α-amylase. The lowest antidiabetically effec-
tive daily intake of mushroom powder was predicted for I. obliquus
with the dose of 3 × 1.148 g/day, while the highest was predicted for
P. linteus 3 × 2.215 g/day. The activity of the extracts investigated herein
could be linked to their chemical compositions previously published by
our research groups. Organic acids, phenolic acids, fatty acids and their
speciﬁc combination in each species contributed to unique in vitro
antidiabetic activity of investigated mushrooms.
Although majority of previous studies showed in vivo antidiabetic
potential of water and polysaccharidic mushroom extracts by different
experimental approaches, our study is the ﬁrst highlighting in vitro
antidiabetic potential by inhibition of α-amylase and α-glucosidase
with methanolic extracts; which makes the investigated species more
promising for the diabetes type-2 treatment by another additional and
different mechanism of action.Acknowledgment
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